The efficacy of edaravone combined with ganglioside for acute cerebral infarction

Abstract

Objective To explore the efficacy of edaravone combined with ganglioside for acute cerebral infarction. Methods 138 patients with acute cerebral infarction from June 2007 to June 2010 were randomly divided into study group and control group, 69 patients for each group. The control group received conventional therapy, aspirin for controlling blood platelets, control of blood pressure and sugar and water to intracranial hypotension, protection of cerebral cells, and improvement of circulation, mannitol, salvia miltiorrhiza, andciticoline; The study group on the edaravone plus ganglioside besides conventional therapy.All the patients were assessed using National Institutes of Health Stroke before and after treatment.Results21 days after therapy, the overall response rate was 82.61%in the study group and 31.88% in the control group, and the total effective rate was 94.41% and 39.13%, respectvely: there was a statistical difference between the two groups (P＜0.05). Scores for NIHSS differed significantly between the two groups (P＜0.05).Conclusions Edaravone combined with ganglioside for acute cerebral infarction is safe and effective and can increase the recovery of nerve function, protect the cerebral tissue, reduce disability rate, and improve the quality of life. Key words: Acute cerebral infarction; Edaravone; Ganglioside